Herantis Pharma Plc.   Report issue

For profit Phase 1 Phase 2
Founded: Helsinki Finland (2008)
Status: Left NME R&D (2023)

Organization Overview

First Clinical Trial
2014
NCT02326090
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Herantis Pharma Plc.

Active Ingredients

Drugs in Phase 2 Trials (4)

Key: Herantis Pharma Plc. (2) Acquired (2)

Cerebral Dopamine Neurotrophic Factor (2 trials)

cis-urocanic acid (4 trials)

lx-1101 (1 trial)

tacrolimus (prograf) (1 trial)

Drugs in Phase 1 Trials (2)

her-096 (1 trial)

lymfactin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Brain Diseases (Phase 2)

Dry Eye Syndromes (Phase 2)

Keratoconjunctivitis Sicca (Phase 2)

Lymphedema (Phase 2)

Movement Disorders (Phase 2)

Neoplasm Metastasis (Phase 2)

Nervous System Diseases (Phase 2)

Neurodegenerative Diseases (Phase 2)

Parkinson Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 9
  • # of Trial APIs: 6